There were a number of interesting posters at the AACR-NCI-EORTC Molecular Targets meeting today. Specifically, two on metastatic pancreatic cancer caught my eye.
Summary of some of the abstract highlights I'm looking forward to checking out at ECCO 2013.
Gilead announced they will file idelalisib in iNHL in 2nd half of 2014. Interim CLL data is also expected then.